

From the Lab to the Clinic

An overview of current
ALS research in Israel



Weizmann Institute of Science
Ebner auditorium

30.10.2013

Scientific Committee:

Chairman: Prof. Daniel Offen, Tel Aviv University

Members of the committee:

Dr. Eran Hornstein, The Weizmann Institute of Science

Dr. Adrian Israelson, Ben Gurion University

Dr. Silvia Mandel, The Technion


Dr. Neta Zach, Prize4Life

**For registration:
www.israls.org.il**

IsrALS's office 04-8252233

Last day of registration: 25.10.13

Registration is free



09:00-09:30 **Welcome reception**
09:30-09:45 **Opening Remarks**
Dov Lautman, IsrALS, President
Prof. Haim Garty, Vice President, Weizmann Institute
Prof. Daniel Offen, Tel Aviv University
09:45-10:00 **Efrat Carmi, IsrALS, CEO**
ALS and IsrALS
10:00-10:15 **Dr. Neta Zach, Prize4Life, Scientific Director**
Prize4Life in Israel

Session I

Chair:

10:15-10:30 **Prof. Vivian Drori, Soraski Medical Center, Tel-Aviv University**
New insights gained in the genetics of ALS from a local specialized center
10:30-10:45 **Dr. Marc Gotkine, Hadassah Medical Center, Hebrew University**
Triathletes are over-represented in a population of patients with ALS
10:45-11:00 **Prof. Dimitrios Karussis, Hadassah Medical Center, Hebrew University**
Autologous transplantation of mesenchymal stem cells secreting neurotrophic factors in ALS patients is safe, with indications of clinical benefit: results of a Phase I/II clinical trial
11:00-11:15 **Shay Rishoni, Prize4Life Israel, CEO**
The golden gate bridge - a patient's vision
11:15-11:30 **Coffee break**

Session II **Molecular basis of ALS and novel therapeutic targets**

Co-Chair:

11:30-11:45 **Dr. Adrian Israelson, Ben Gurion University, Targeting misfolded SOD1 as a therapy for ALS**
11:45-12:00 **Dr. Eran Perlson, Tel Aviv University, The molecular communication mechanism of motor neuron survival and synapse maintenance**

12:00-12:15 **Dr. Eran Hornstein, The Weizmann Institute of Science**
Causes and consequences of dysregulated microRNAs in ALS
12:15-12:30 **Prof. Esther Priel, Ben Gurion University**
Telomerase Increasing compounds protected motor neurons like cells from oxidative stress and delayed the onset and progression of ALS in animal model.
12:30-12:45 **Dr. Rachel G. Lichtenstein, Ben Gurion University**
The function of N-glycans attached to the Fc domain of IgGs in the progression of ALS
12:45-13:45 **Lunch**
13:45-14:15 **Poster session**

Session III **ALS preclinical drug development**

Chair:

14:15-14:30 **Dr. Adrian Israelson, Ben Gurion University**
Prof. Daniel Offen, Tel Aviv University
New synergistic genetic treatment extends survival of ALS mice
14:30-14:45 **Prof. Michal Schwartz, The Weizmann Institute for Science**
Activation of the brain's choroid plexus for leukocyte trafficking as a therapeutic approach for ALS
14:45-15:00 **Dr. Elhanan Pinner, Neurim Pharmaceuticals**
A potential role for CD44V10 in ALS
15:00-15:15 **Prof. Ilana Gozes, Tel Aviv University**
NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection the spinal cord and the brain against impairments in axonal transport
15:15-15:30 **Prof. Beka Solomon, Tel Aviv University**
Down regulation of Amyloid Precursor Protein processing ameliorate the pathology of ALS
15:30-15:45 **Prof. Miguel Weil, Tel Aviv University**
Personalizing ALS treatment: Direct and simultaneous drug high content analysis screening on cell-based model from several ALS patients
15:45-16:00 **Summary**